Effects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure — MAPAKI  

Shock Clinical Trial

Official title: Effects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure : a Pilot Study for the Individualization of Mean Arterial Pressure

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to assess the effect of a higher mean arterial pressure on renal function for patients with shock and elevated central venous pressure.

Clinical Trial Description

Current recommandation for mean arterial pressure (MAP) target is 65 mmHg for septic shock, but optimal target to prevent acute renal failure (ARF) remains unknown. High central venous pressure (CVP) can lead to acute renal failure through venous congestion , and is associated with acute renal failure in intensive care unit. A decrease of renal perfusion pressure, defined by MAP - CVP, has been shown to be associated with risk of acute renal failure. The main objective of this trial is to evaluate if an optimisation of renal perfusion pressure, by a higher MAP when CVP is high (≥ 12 cmH2O), can improve renal function. In this interventional monocenter trial, each patient will be evaluated during 2 consecutive periods of 6 hours, with a temporary MAP target - Target at 65-70mmHg during 6 hours - Target at 80-85mmHg during 6 hours Patients will be randomized into two groups to define the order of targets. There will be a stratification on previous arterial hypertension. Renal function will be measured at the end of each period. ;

Related Conditions & MeSH terms

• Shock

• NCT number: NCT05655065
• Study type: Interventional
• Source: University Hospital, Angers
• Contact: Nicolas FAGE, MD
• Phone: +332 41 35 36 37
• Email: nicolas.fage@chu-angers.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2023
• Completion date: December 31, 2026